SCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerp's Activity Against Resistant Fungal Pathogens, Including Candida auris
Stock Information for SCYNEXIS Inc.
Loading
Please wait while we load your information from QuoteMedia.